In episode 267, James and Mike finally get to the first PREMIUM podcast of 2015 – and boy is it something. We discuss a new paper put out by the Edmonton gang on who actually contributes to primary care guidelines, we talk about a new systematic review of mild hypertension treatment, and finally discuss a NEJM article on the duration of dual antiplatelets. At the end we both agree this podcast was really something.

Show notes

1) Contributors to primary care guidelines 

Can Fam Physician 2015;61:52-8 

2) Effects of Blood Pressure Reduction in Mild Hypertension 

A Systematic Review and Meta-analysis 

Ann Intern Med. 2015;162(3):184-191. doi:10.7326/M14-0773

3) Twelve or 30 Months of Dual Antiplatelet Therapy  after Drug-Eluting Stents 

N Engl J Med 2014;371:2155-66

In episode 266, James and Mike finally get to the end of listener questions. We talk about NSAIDs and inflammation, cognitive impairment and statins, dosing of antibiotics, antidepressants and efficacy, and antiplatelets and ethnicity. We give answers which either clarify or confuse the issues.

Show notes

1) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

Lancet 2009;373:746-58

2) Selective publication of antidepressant trials and its influence on apparent efficacy

N Engl J Med 2008;358:252-60

3) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

Am J Psychiatry 2006;163:185-94

In episode 265, Mike and James continue with listener questions. We tackle issues around calories, alcohol intake, nutrition, diabetes and so much more. We provide answers and so much less.

Show notes

1) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

Lancet 2005;366:2026-33